Literature DB >> 24281309

Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial.

Dorothee Siepmann1, Tobias Lotts, Christine Blome, Matthias Braeutigam, Ngoc Quan Phan, Trude Butterfass-Bahloul, Matthias Augustin, Thomas A Luger, Sonja Ständer.   

Abstract

BACKGROUND: In the treatment of atopic dermatitis, pimecrolimus has high antipruritic effects.
OBJECTIVE: To investigate the efficacy of 1% pimecrolimus cream in comparison to 1% hydrocortisone cream in non-atopic prurigo nodularis (PN).
METHODS: A randomized, controlled, double-blind study with intraindividual randomization was done in 30 patients (17 females, 13 males; mean age 58.5 years) with PN.
RESULTS: Pruritus intensity decreased significantly (p < 0.001) on both treated sides as early as after 10 days of treatment; scratch lesions improved (p < 0.001). Quality of life as assessed by the Dermatology Life Quality Index improved significantly. However, a significant advantage of pimecrolimus over hydrocortisone was not found.
CONCLUSION: The results suggest that the non-steroid pimecrolimus is an effective alternative for PN treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24281309     DOI: 10.1159/000355671

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  12 in total

1.  [56-year-old male with erythematous, excoriated papules and nodules on the extremities, shoulders and buttocks : Preparation for the specialist examination: part 12].

Authors:  Vincent Hoffmann; Claudia Zeidler; Sonja Ständer
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

Review 2.  [Prurigo. Clinical definition and classification].

Authors:  F Schedel; C Schürmann; D Metze; S Ständer
Journal:  Hautarzt       Date:  2014-08       Impact factor: 0.751

Review 3.  [New treatment options for chronic pruritus].

Authors:  C Zeidler; B Pfleiderer; S Ständer
Journal:  Hautarzt       Date:  2016-08       Impact factor: 0.751

4.  [Chronic prurigo].

Authors:  M P Pereira; T Nau; C Zeidler; S Ständer
Journal:  Hautarzt       Date:  2018-04       Impact factor: 0.751

5.  Abnormal Plasma Levels of Steroids and Their Ratios in Patients With Prurigo Nodularis: A Pilot Study.

Authors:  Liuxi Chu; Xin Shu; Yan Wu; Haoran Yang; Qin Lu; Huihua Deng
Journal:  Front Physiol       Date:  2022-06-28       Impact factor: 4.755

6.  The impact of prurigo nodularis on quality of life: a systematic review and meta-analysis.

Authors:  Sherief R Janmohamed; Eran C Gwillim; Muhammad Yousaf; Kevin R Patel; Jonathan I Silverberg
Journal:  Arch Dermatol Res       Date:  2020-10-27       Impact factor: 3.017

Review 7.  Chronic Pruritus: Current and Emerging Treatment Options.

Authors:  Manuel P Pereira; Sonja Ständer
Journal:  Drugs       Date:  2017-06       Impact factor: 11.431

8.  [Therapy of prurigo nodularis].

Authors:  C Zeidler; S Ständer
Journal:  Hautarzt       Date:  2014-08       Impact factor: 1.198

9.  Investigator's Global Assessment of Chronic Prurigo: A New Instrument for Use in Clinical Trials.

Authors:  Claudia Zeidler; Manuel P Pereira; Matthias Augustin; Mary Spellman; Sonja Ständer
Journal:  Acta Derm Venereol       Date:  2021-02-17       Impact factor: 3.875

10.  Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction.

Authors:  Manuel P Pereira; Claudia Zeidler; Joanna Wallengren; Jon Anders Halvorsen; Elke Weisshaar; Simone Garcovich; Laurent Misery; Emilie Brenaut; Ekin Şavk; Nikolay Potekaev; Andrey Lvov; Svetlana Bobko; Jacek C Szepietowski; Adam Reich; Agnieszka Bozek; Franz J Legat; Martin Metz; Markus Streit; Esther Serra-Baldrich; Margarida Gonçalo; Michael Storck; Teresa Nau; Vincent Hoffmann; Sabine Steinke; Ina Greiwe; Martin Dugas; Matthias Augustin; Sonja Ständer
Journal:  Acta Derm Venereol       Date:  2021-02-17       Impact factor: 3.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.